Gayatri Bioorganics Limited

As of June 30, 2026, Gayatri Bioorganics Limited carries a market capitalization of 589.34M, placing it among publicly traded companies globally. Its enterprise value stands at 589.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gayatri Bioorganics Limited has 78.79M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 25.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 589.34M versus a market cap of 589.34M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 7.79M in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Gayatri Bioorganics Limited's stock has declined approximately 34.10% over the past 52 weeks. The 50-day moving average sits at 7.71, while the 200-day moving average is 11.31.

Over the twelve months ended June 30, 2026, Gayatri Bioorganics Limited generated 23.37M in revenue and converted that into -9.51M in net income, yielding earnings per share of -0.12. EBITDA reached -5.67M, while operating income came in at -5.67M.

Over the twelve months ended June 30, 2026, Gayatri Bioorganics Limited posted a gross margin of 7.79, reflecting its pricing power and cost economics. The operating margin of -24.25 and net profit margin of -40.68 provide insight into operational efficiency.